English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November.
Tag: Vaccine
What We Know: Mount Sinai to Host COVID-19 Research Symposium
The COVID-19 Research Symposium, hosted by the Mount Sinai Clinical Intelligence Center (MSCIC), is a one-day comprehensive review of advances in research by the Mount Sinai Health System to better understand and treat the coronavirus known as COVID-19.
MTU, UMass researchers preserve viral vaccines without refrigeration
Half of vaccines are wasted annually because they aren’t kept cold. Michigan Tech and UMass Amherst chemical engineers have discovered a way to stabilize viruses in vaccines with proteins instead of temperature.
Expert available to discuss best methods for communicating about COVID-19 vaccine
On Monday, Pfizer announced early results from its coronavirus vaccine trial that showed their vaccine is more than 90 percent effective – signaling that the vaccine may be closer than ever to being distributed. Katharine Head, an associate professor of…
.@umichsph researcher @rmalosh discusses the results of the interim efficacy analysis, shared today by Pfizer and BioNTech, is available to discuss with the media.
Ryan Malosh, assistant research scientist at the University of Michigan School of Public Health, can comment on today’s announcement by Pfizer and BioNTech. His research focuses on vaccine effectiveness, epidemiology and transmission of respiratory viruses, and social determinants of acute…
Fighting Zika? Call in the T cells
In a new Science Advances study, Shresta and her colleagues at LJI report that the immune system’s T cells have the power to prevent Zika infection in mice. This finding suggests that effective Zika vaccines need to activate T cells to work alongside antibodies.
Iowa awards $2 million CARES Act grant to universities to study COVID-19 nanovaccine
The state of Iowa has designated $2 million in federal CARES Act funding to support university research and development of a nanovaccine to protect against COVID-19 infections. Researchers at Iowa State University and the University of Iowa will work together on a needle-free, single-dose nanovaccine.
Surgeon General expects COVID-19 vaccine to be available by year’s end
In a wide-ranging talk with UCLA Health physicians, Wednesday, Oct. 28, United States Surgeon General Jerome Adams, MD, MPH, addressed the politicization of the pandemic and the means of containing the spread of COVID-19. He also offered hope that a vaccine for the virus will be available by year’s end.
Sociology professors publish research on vaccine refusal
Study examines “personal belief exemptions” (PBEs) to childhood vaccine requirements among certain communities in California.
Study: Turning a coronavirus protein into a nanoparticle could be key to an effective COVID-19 vaccine
One of the proteins on the virus – located on the characteristic COVID spike – has a component called the receptor-binding domain, or RBD, which is its “Achilles heel.” That is, he said, antibodies against this part of the virus have the potential to the neutralize the virus.
Key details about broadly neutralizing antibodies provide insights for universal flu vaccine
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
Rutgers Expert Available to Discuss Ethics of Human Challenge Trials
The first human challenge trial of a potential coronavirus vaccine — in which healthy volunteers are infected with the virus after being given different vaccines under development — is planned for January. A Rutgers expert is available to discuss the…
Building “ToxAll” — a smart, self-assembling nano-vaccine to prevent toxoplasmosis
A team of researchers at the University of Chicago have developed a self-assembling nanoparticle to create a toolbox for treating infections such as Toxoplasma gondii, a serious parasitic infection.
Serology Study Provides Critical Insight into COVID-19 Immune Response
New research in Clinical and Translational Immunology, provides a clearer picture of the protective antibodies induced by SARS-CoV-2 and their role in serious illness and what’s needed for full protection.
CARES Act funds major upgrade to Corona supercomputer for COVID-19 work
With funding from the Coronavirus Aid, Relief and Economic Security (CARES) Act, Lawrence Livermore National Laboratory, chipmaker AMD and information technology company Supermicro have upgraded the supercomputing cluster Corona, providing additional resources to scientists for COVID-19 drug discovery and vaccine research
Story Tips: Remote population counting, slowing corrosion and turning down the heat
ORNL story tips: Remote population counting, slowing corrosion and turning down the heat
Vaccine Opposition Online Uniting Around ‘Civil Liberties’ Argument
Anti-vaccination discourse on Facebook increased in volume over the last decade, coalescing around the argument that refusing to vaccinate is a civil right, according to a study published today in the American Journal of Public Health.
New Biomarkers for Glioma Treatment Response
Biomarkers using mass cytometry can assess patient response to an emerging vaccine for a specific pediatric brain tumor, according to a recent multi-center study published in the Journal of Clinical Investigation.
Science Snapshots September 2020
2D Electronics, Plant Biofactories, Transforming Waste, and Vaccine Development.
New vaccine strategy harnesses ‘foot soldier’ T-cells to provide protection against influenza
As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of Wisconsin–Madison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.
Rutgers Expert Available to Discuss Communicating About COVID-19 Vaccine
New Brunswick, N.J. (Sept. 17, 2020) – Rutgers University–New Brunswick Professor William Hallman is available for interviews on how to communicate with the public about a potential COVID-19 vaccine. “For a COVID-19 vaccine to be embraced by the public, officials can’t…
Injectable hydrogel could someday lead to more effective vaccines
Researchers reporting in ACS Central Science developed an injectable hydrogel that allows sustained release of vaccine components, increasing the potency, quality and duration of immune responses in mice.
Professor: Information key to COVID-19 vaccine acceptance
Glen Nowak, director of the Center for Health and Risk Communication at the University of Georgia, co-authored a Perspective article addressing one of the most pressing topics facing the United States: achieving high acceptance of a vaccine for COVID-19. The…
Rutgers Bioethicist Available to Discuss Who May Get COVID-19 Vaccine First
Rutgers scholar Nir Eyal is available to discuss the ethics around who will be among the first in line to receive a COVID-19 vaccine when it’s available to the public. “Unlike other therapy treatments, vaccines help prevent the spread of…
Lack of Black and Hispanic Patients Could Jeopardize COVID-19 Vaccine
Rockville, Md. (September 3, 2020)—Only 10% of the 350,000 people who recently signed up for a coronavirus vaccine clinical trial are Black and Hispanic, according to CNN. This low number of participants is especially concerning given the disproportionately higher rates…
Thomas Jefferson University Awarded $508,000 by the Commonwealth to support CoraVax™, a patented COVID-19 vaccine
Thomas Jefferson University Awarded $508,000 by the Commonwealth to support CoraVax™, a patented COVID-19 vaccine
Preclinical study of COVID-19 vaccine candidate shows potent T-cell responses
Preclinical results for a COVID-19 vaccine candidate appear to distinguish this vaccine candidate from other vaccine candidates. A single nasal dose in mice gave a potent T-cell response at the lung mucus layer, including killer CD8+ T-cells that can recognize and kill virally infected cells.
Nasal vaccine against COVID-19 prevents infection in mice
Scientists at Washington University School of Medicine in St. Louis have developed a vaccine that targets the SARS-CoV-2 virus, can be given in one dose via the nose and is effective in preventing infection in mice susceptible to the novel coronavirus. The investigators next plan to test the vaccine in nonhuman primates and humans to see if it is safe and effective in preventing COVID-19 infection.
Studying viral outbreaks in single cells could reveal new ways to defeat them (video)
Many viruses mutate so quickly that identifying vaccines or treatments is like trying to hit a moving target. Now, scientists report a new technique that can detect minor changes in RNA sequences. They present their results today at the American Chemical Society Fall 2020 Virtual Meeting & Expo.
Keck Medicine of USC enrolling volunteers for phase 3 clinical trial for COVID-19 vaccine
Keck Medicine of USC launches phase 3 trial for COVID-19 vaccine. To ensure access for underrepresented and vulnerable populations, researchers are setting up a satellite location in the meat-packing community of Vernon, CA.
COVID-19 Vaccine Candidate Tested at University of Kentucky Shows Positive Preclinical Results
PDS Biotechnology, a clinical stage immunotherapy company, has announced positive results from preclinical testing conducted at the University of Kentucky College of Medicine of its COVID-19 vaccine candidate, PDS0203.
Experimental COVID-19 vaccine prevents severe disease in mice
Researchers at Washington University School of Medicine in St. Louis have created a COVID-19 vaccine candidate from a replicating virus. This experimental vaccine has proven effective at preventing pneumonia in mice.
COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.
New intranasal vaccine platform provides potential for more effective vaccines with fewer side effects
A new study at the University of Chicago and Duke University finds that a new type of intranasal vaccine induces a strong immune response in lungs, with possible implications for COVID-19. The system uses nanofibers tagged with antigens to prime the immune system against a potential invasion.
Two-Thirds of Adults Support Vaccination, National Survey Says
When a COVID-19 vaccine becomes available, 66 percent of adults are likely to get vaccinated, and have their children vaccinated as well, according to a new nationwide survey led by researchers from Rutgers University–New Brunswick, Northeastern, Harvard, and Northwestern universities.
Tip Sheet: COVID-19 vaccines, COVID-19 and cancer patients, smoking cessation apps, structural racism in medicine – and more
Summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.
Immunization Programs Yield High “Return on Investment,” Saving Hundreds of Billions of Dollars
Immunization programs offered in low- and middle-income countries provide a high “return on investment” in terms of the economic costs of diseases that are prevented and the values of lives that would have been lost.
Single-shot COVID-19 vaccine protects non-human primates
A leading COVID-19 vaccine candidate developed at Beth Israel Deaconess Medical Center creates the groundwork for a newly launched COVID-19 vaccine clinical trial
Baylor Scott & White Research Institute Expands Efforts in the Fight Against COVID-19
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment
Recent animal experiments showed that LEAPS COVID 19 conjugates induced faster and much higher than expected antibody responses against a non-mutating region of the virus that causes COVID 19, after only one injection.
Coronavirus antibodies fall dramatically in first 3 months after mild cases of COVID-19
A study by UCLA researchers shows that in people with mild cases of COVID-19, antibodies against SARS-CoV-2 — the virus that causes the disease — drop sharply over the first three months after infection, decreasing by roughly half every 73 days. If sustained at that rate, the antibodies would disappear within about a year.
Researchers develop new tools to rapidly test activity of anti-coronavirus antibodies
Researchers at The Rockefeller University in New York have developed new tools to rapidly test the ability of antibodies to neutralize SARS-CoV-2, the novel coronavirus responsible for the COVID-19 pandemic. The approach, described today in the Journal of Experimental Medicine (JEM), will help researchers understand whether patients are susceptible to reinfection by SARS-CoV-2 and assess the effectiveness of experimental vaccines, as well as develop antibody-based therapies against the disease.
UM to Launch COVID-19 Vaccine Testing Site for the COVID-19 Prevention Trials Network
The University of Miami Miller School of Medicine has been selected to be part of the National Institutes of Health COVID-19 Prevention Trials Network (CoVPN) to launch clinical trials to test investigational COVID-19 vaccines.
A Nanomaterial Path Forward for COVID-19 Vaccine Development
From mRNA vaccines entering clinical trials, to peptide-based vaccines and using molecular farming to scale vaccine production, the COVID-19 pandemic is pushing new and emerging nanotechnologies into the frontlines and the headlines.
Nanoengineers at UC San Diego detail the current approaches to COVID-19 vaccine development, and highlight how nanotechnology has enabled these advances, in a review article in Nature Nanotechnology published July 15.
San Antonio Partnership for Precision Therapeutics Fuels COVID-19 Research
Fueling transformative research through collaboration, the San Antonio Partnership for Precision Therapeutics (SAPPT) announces the funding of three more collaborative COVID-19 research efforts in San Antonio. SAPPT has awarded more than $600,000 to fund these projects, following the funding of a SARS CoV-2 vaccine project announced in April of this year.
Tiny mineral particles are better vehicles for promising gene therapy
University of Wisconsin–Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination — including a COVID-19 vaccine from Moderna Therapeutics that has advanced to clinical trials with humans.
Study Explores Possible Candidates for Vaccine Treatment for Liver Cancer
Article title: Experimental analysis of T cell epitopes for designing liver cancer vaccine predicted by system-level immunoinformatics approach Authors: Syed Aun Muhammad, Sidra Zafar, Samana Zahra Rizvi, Imran Imran, Fahad Munir, Muhammad Babar Jamshed, Amjad Ali, Xiaogang Wu, Numan Shahid,…
NEW STRATEGY EMERGES FOR VACCINE AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCAL AUREUS
Experiments in mice have shown early success in vaccinating them against potentially deadly bacterial infections, such as methicillin-resistant Staphylococcal aureus, or MRSA, the strain resistant to most drug treatments.
SLU’s Hoft Is Named to National Vaccine Advisory Committee
Saint Louis University researcher Daniel Hoft, M.D., Ph.D., has been named to the National Vaccine Advisory Committee. Hoft was named a voting member of the group on June 8.
COVID-19 vaccine to be tested in UIC clinical trial
The University of Illinois at Chicago will soon test a vaccine for COVID-19. Expected to launch July 9, the trial — a phase 3 clinical study — will test the efficacy of a vaccine developed by biotech company Moderna.